You just read:

Medicare Establishes Final Local Coverage Determination (LCD) for Use of the Oncotype DX® Genomic Prostate Score™ Test in Patients with Favorable Intermediate-risk Prostate Cancer Effective October 9, 2017

News provided by

Genomic Health, Inc.

Aug 24, 2017, 08:00 ET